Centre For HIV And STI Publications

 Publications
 
CHIVSTI – Virology (Morris Lab)
 

2011

 
Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, Chakauya E, O'Keefe BR, Chikwamba R, and Morris L. (2011) Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol:(17): 9039-50.  (IF: 5.189)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Binding+of+the+mannose-specific+lectin%2C+griffithsin%2C+to+HIV-1+gp120+exposes+the+CD4-binding+site
 
Bonsignori M, Hwang K, Chen X, Tsao C, Morris L, Gray E, Marshall D, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O’Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori D, Kepler TB, Tomaras GD, Alam SM, Liao H, Haynes BF. (2011)  Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. J Virol (19):9998-10009.  (IF: 5.189)

Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Analysis+of+a+Clonal+Lineage+of+HIV-1+Envelope+V2%2FV3+Conformational+Epitope-Specific+Broadly+Neutralizing+Antibodies+and+Their+Inferred+Unmutated+Common+Ancestors

 
Coetzer M, Nedellec R, Cilliers T, Meyers T, Morris L and Mosier DE. (2011)  Extreme Genetic Divergence Is Required for Coreceptor Switching in HIV-1 Subtype C. JAIDS: 56: 9-15

Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Extreme+Genetic+Divergence+Is+Required+for+Coreceptor+Switching+in+HIV-1+Subtype+C

Dlamini JN, Hu Z, Ledwaba J, Morris L, Maldarelli FM, Dewar RL, Highbarger HC, Somaroo H, Sangweni P, Follmann DA, Pau AK.  (2011) Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.   JAIDS; 58: 304-308 (IF: 4.262)

Link:
http://www.ncbi.nlm.nih.gov/pubmed/21694608
 
El-Khatib Z,, Ekström AM, Coovadia A, Abrams EJ, Petzold M, Katzenstein D, Morris L,  Kuhn L. (2011)  Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa – a prospective cohort study. BMC Public Health: 11(1): 88 (IF: 2.36)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Adherence+and+virologic+suppression+during+the+first+24+weeks+on+antiretroviral+therapy+among+women+in+Johannesburg%2C+South+Africa+%E2%80%93+a+prospective+cohort+study
 
El-Khatib Z, DeLong A, Katzenstein D, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Petzold M, Morris L and Kantor R. (2011) Drug Resistance Patterns and Virus Re-Suppression among HIV-1 Subtype C Infected Patients Receiving Non-Nucleoside Reverse Transcriptase Inhibitors in South Africa.  J AIDS Clinic Res: 2:2  (IF: 4.9)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Drug+Resistance+Patterns+and+Virus+Re-Suppression+among+HIV-1+Subtype+C+Infected+Patients+Receiving+Non-Nucleoside+Reverse+Transcriptase+Inhibitors+in+South+Africa
 
El-Khatib Z, Katzenstein D, Marrone G, Laher F, Mohapi L, Petzold M, Morris L, Ekström, AM.  (2011) Adherence to drug-refill a useful early warning indicator of long-term virologic and immunologic failure among HIV patients on 1st line ART in South Africa. PlosOne: 6 (3) e17518 (IF: 4.4)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Adherence+to+drug-refill+a+useful+early+warning+indicator+of+long-term+virologic+and+immunologic+failure+among+HIV+patients+on+1st+line+ART+in+South+Africa
 
Firnhaber C, Azzoni L, Foulkes AS, Gross R, Yin X, Van Amsterdam D, Schulze D, Glencross DK, Stevens W, Hunt G, Morris L, Fox L, Sanne I, Montaner LJ.  (2011) Randomized Trial of Time-Limited Interruptions of Protease Inhibitor-based Antiretroviral Therapy (ART) vs. Continuous Therapy for HIV-1 infection.  PlosOne: 6(6): e21450. (IF: 4.4)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Randomized+Trial+of+Time-Limited+Interruptions+of+Protease+Inhibitor-based+Antiretroviral+Therapy+%28ART%29+vs.+Continuous+Therapy+for+HIV-1+infection
 
Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L and the CAPRISA 002 study team. (2011) The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol.: 85: 4828-4840 (IF: 5.189)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=The+neutralization+breadth+of+HIV-1+develops+incrementally+over+four+years+and+is+associated+with+CD4%2B+T+cell+decline+and+high+viral+load+during+acute+infection
 
Gray ES, Moody MA, Wibmer CK, Chen X, Marshall D, Amos J, Moore PL, Foulger A, Yu J, Lambson B, Abdool Karim S, Whitesides J, Tomaras GD, Haynes BF, Morris L, and Liao H. (2011) Isolation of a monoclonal antibody targeting the alpha-2 helix of gp120 1 representing the 2 initial autologous neutralizing antibody response in an HIV-1 subtype C infected individual. J. Virol: 85: 7719-7729 (IF: 5.189)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Isolation+of+a+monoclonal+antibody+targeting+the+alpha-2+helix+of+gp120+1+representing+the+2+initial+autologous+neutralizing+antibody+response+in+an+HIV-1+subtype+C+infected+individual
 
Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, Kuhn L. (2011) HIV-1 drug resistance at antiretroviral treatment in children previously exposed to single-dose nevirapine. AIDS: 25: 1461-1469.   (IF: 6.348)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/21633285
 
Li J, Lipscomb JT, Wei X, Martinson NA, Morris L, Heneine W, Johnson JA.  (2011) Detection of Low-Level K65R Variants in Nucleoside Reverse Transcriptase Inhibitor-NJaive Chronic and Acute HIV-1 subtype C infections.  J Infect Dis: 203 (6): 798-802. (IF: 6.288)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Detection+of+Low-Level+K65R+Variants+in+Nucleoside+Reverse+Transcriptase+Inhibitor-NJaive+Chronic+and+Acute+HIV-1+subtype+C+infections
 
Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, and Morris L, and the CAPRISA 002 study.  (2011) Potent and broad neutralization of HIV-1 subtype C viruses by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J. Virol: 85: 3128-3141 (IF: 5.189)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Potent+and+broad+neutralization+of+HIV-1+subtype+C+viruses+by+plasma+antibodies+targeting+a+quaternary+epitope+including+residues+in+the+V2+loop
 
Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall D, Chen B, Parks R, Foulger A, Jaeger F, McParland M, Biliska M, Gray E, Abdool Karim S, Kepler TB, Whitesides J, Montefiori D, Moody MA, Liao H, Haynes BF.  (2011) Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B cell Sorting. PlosOne:6: (9) e23532
(IF: 4.4)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Isolation+of+a+Human+Anti-HIV+gp41+Membrane+Proximal+Region+Neutralizing+Antibody+by+Antigen-Specific+Single+B+cell+Sorting
 
Taylor BS, Hunt G, Abrams EJ, Coovadia A, Meyers T, Sherman G, Strehlau R, Morris L, Kuhn L.  (2011) Rapid development of antiretroviral drug resistance mutations in HIV-infected children initiating protease inhibitor-based therapy less than 2 years of age in South Africa. AIDS Res. Hum. Retro. 2011: 27 (9):945-56. (IF: 2.082)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Rapid+development+of+antiretroviral+drug+resistance+mutations+in+HIV-infected+children+initiating+protease+inhibitor-based+therapy+less+than+2+years+of+age+in+South+Africa
 
Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X,, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool-Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L.  (2011) Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-infected Individuals. J.Virol: 85: 11502-11519 (IF: 5.189)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Polyclonal+B+Cell+Responses+to+Conserved+Neutralization+Epitopes+in+a+Subset+of+HIV-1-infected+Individuals
 
Zazzi M, Kaiser R, Sonnerborg A, Struck D, Altmann A, Prosperi M, Rosen-Zvi M, Petroczi A, Peres Y, Schulter E, Boucher CA, Brun-Vezinet F, Harrigan PR, Morris L, Obermeier M, Perno CF, Phanuphak P, Pillay D, Shafer RW, Vandamme AM, van Laethem K, Wensing AM, Lengauer T, Incardona F. (2011) Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). HIV Med.: 12: 211-218 (IF: 3.575)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Prediction+of+response+to+antiretroviral+therapy+by+human+experts+and+by+the+EuResist+data-driven+expert+system+%28the+EVE+study%29.
 

2012

Alexandre KB, Gray ES, Mufhandu H, McMahon JB, Chakauya E, O’Keefe BR, Chikwamba R, Morris L. (2012) The lectins Griffithsin, Cyanovirin-N and Scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4+ cells.  Virology: 423: 175-186

Link:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274779/


Archary D, Rong R, Gordon ML, Boliar S, Madiga M, Gray ES, Dugast AS, Hermanus T, Goulder PJ, Coovadia HM, Werner L, Morris L, Alter G, Derdeyn CA, Ndung'u T. (2012) Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology. Nov 25;433(2):410-20.
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Characterization+of+anti-HIV-1+neutralizing+and+binding+antibodies+in+chronic+HIV-1+subtype+C+infection
 
Conradie F, Wilson D, Basson A, de Oliveira T, Hunt G, Joel D, Papathanasopoulos M, Preiser W, Klausner J, Spencer D, Stevens W, Venter F, van Vuuren C, Levin L, Meintjes G, Orrell C, Sunpath H, Rossouw T, van Zyl G. (2012) The 2012 southern African ARV drug resistance testing guidelines. SAJHIVMED November, Vol. 13 No. 4
Link:
http://www.sahivsoc.org/upload/documents/The%202012%20southern%20African%20ARV%20drug%20resistance%20testing%20guidelines.pdf
 
Hassam M, Basson AE, Liotta DC, Morris L, van Otterlo WAL, Pelly SC.  Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors. (2012) ACS Medicinal Chemistry Letters. ACS Med. Chem. Lett., 3 (6), pp 470–475
Link:
http://pubs.acs.org/doi/abs/10.1021/ml3000462?tokenDomain=campaign&tokenAccess=noteworthy&forwardService=showFullText&journalCode=amclct
 
Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Ramaswamy M, Sattentau QJ, Tolazzi M, Schuitemaker H, Willems B, Wrin T, Fenyo EM, Scarlatti.  (2012) International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II.  PLoS ONE : 7: 5: e36438 (IF: 4.4)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=International+Network+for+Comparison+of+HIV+Neutralization+Assays%3A+The+NeutNet+Report+II
 
Hunt GM, Ledwaba J, Basson AE, Moyes J, Cohen C, Singh B, Bertagnolio S, Jordan MR, Puren A, Morris L.  (2012) Surveillance of Transmitted HIV-1 Drug Resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009.  Clinical Infectious Diseases: 54: S334-S338 (IF: 8.186)
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Surveillance+of+Transmitted+HIV-1+Drug+Resistance+in+Gauteng+and+KwaZulu-Natal+Provinces%2C+South+Africa%2C+2005-2009
 
Jordan MR, Bennett DE, Wainberg MA, Havlir D, Hammer S, Yang C, Morris L, Peeters M, Wensing AM, Parkin N, Nachega JB, Phillips A, De Luca A, Geng E, Calmy A, Raizes E, Sandstrom P, Archibald CP, Perriëns J, McClure CM, Hong SY, McMahon JH, Dedes N, Sutherland D, Bertagnolio S. (2012) Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011.  Clin. Infectious Dis:54 S245
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Update+on+World+Health+Organization+HIV+Drug+Resistance+Prevention+and+Assessment+Strategy%3A+2004-2011
 
Klein F, Gaebler C, Mouquet H, Sather N, Lehmann C, Scheid J, Kraft Z, Liu Y, Pietzsch J, Hurley A, Feizi T, Morris L, Walker BD, Fatkenheuer G, Seaman MS, Stamatatos L, Nussenzweig MC.(2012)  Broad neutralization by a combination of antibodies to the CD4 binding site and a new conformational epitope on the HIV envelope protein. .JEM vol. 209 no. 8 1469-1479
Link:
http://www.ncbi.nlm.nih.gov/pubmed/22826297
 
Kuhn L, Coovadia A, Strehlau R, Martens L, Hu C, Meyers T, Sherman G, Hunt G, Persaud D, Morris L, Tsai W, Abrams EJ.  (2012) Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. Jul;12(7):521-302012. 
Link:
http://www.ncbi.nlm.nih.gov/pubmed/22424722

Lynch RM, Tran L, Louder MK, Cohen M, and the CHAVI 001 clinical team, DerSimonian R,  Euler Z, Gray ES, Abdool Karim S, Kirchherr J, Montefiori D, Sibeko S, Soderberg K, Tomaras G, Yang Z, Nabel GJ, Schuitemaker H, Morris L, Haynes BF, Mascola JR. (2012) The development of CD4 binding site antibodies during HIV-1 infection. J Virol. Jul;86(14):7588-95

Link:
http://www.ncbi.nlm.nih.gov/pubmed/22573869
 
Moore P.L., Gray E.S., Wibmer C.K., Bhiman J.N., Nonyane M., Sheward D., Hermanus T., Bajimaya S., Tumba N.L., Abrahams M., Lambson, B.E., Ranchobe, N., Ping L., Ngandu N., Abdool Karim Q., Abdool Karim S.S., Swanstrom R.I., Seaman M.S., Williamson C., Morris L.. (2012) Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nature Medicine 18, 1688–1692
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Evolution+of+an+HIV+glycan-dependent+broadly+neutralizing+antibody+epitope+through+immune+escape
 
Mufhandu HT, Gray ES, Madiga MC, Tumba N, Alexandre KB, Khoza T, Wibmer CK, Moore PL, Morris L, Khati M.  (2012) UCLA1, a Synthetic Derivative of a gp120 RNA Aptamer, Inhibits Entry of the Human Immunodeficiency Virus Type-1 Subtype C. J Virol. May; 86(9):4989-99
Link:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347371/
 
Overbaugh J, Morris L.  (2012) The antibody response against HIV.  Chapter in book “HIV – From Biology to Prevention and Treatment”.  Cold Spring Harb Perspect Med doi: 10.1101/ cshperspect.a007039
Link: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253031/
 

2013:

 
Alexandre K, Moore PL, Nonyane M, Gray ES, Ranchobe R, Chakauya E; McMahon J, O’Keefe B, Chikwamba R, Morris L. (2013) Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. Virology 446 (2013) 66-76
Link:
http://www.sciencedirect.com/science/article/pii/S004268221300439X
 

Andersson E, Shao W, Bontell I, Cham F, Cuong DD, Wondwossen A, Morris L, Hunt G, Sönnerborg A, Bertagnolio S, Maldarelli F, Jordan MR. (2013). Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. Infection, Genetics and Evolution 18 (2013) 125–131

Link:

http://www.ncbi.nlm.nih.gov/pubmed/?term=Evaluation+of+sequence+ambiguities+of+the+HIV-1+pol+gene+as+a+method+to+identify+recent+HIV-1+infection+in+transmitted+drug+resistance+surveys

Georgiev IS, Doria-Rose NA, Zhou T, Do Kwon Y, Staupe RP, Moquin S, Chuang G-Y, Louder MK, Schmidt SD, Altae-Tran HR, Bailer RT, McKee K, Nason M, O’Dell S, Ofek G, Pancera M, Srivatsan S, Shapiro L, Connors M, Migueles SA, Morris L, Nishimura Y, Martin MA, Mascola JR, Kwong PD. (2013) Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. Science: Vol. 340 no. 6133 pp. 751-756. DOI: 10.1126/science.1233989.

Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Delineating+Antibody+Recognition+in+Polyclonal+Sera+from+Patterns+of+HIV-1+Isolate+Neutralization
 
Hoffmann CJ, Ledwaba J, Li J-F, Johnston V, Hunt G, Fielding KL , Chaisson RE, Churchyard GJ, Grant AD, Johnson JA, Charalambous S, Morris L. (2013). Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther. 2013 Jun 10. doi: 10.3851/IMP2652
Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Resistance+to+tenofovir-based+regimens+during+treatment+failure+of+subtype+C+HIV-1+in+South+Africa
 
Johnston V, Cohen K, Weisner L, Morris L, Ledwaba J, Fielding K, Charalambous S, Churchyard G, Phillips A, Grant A. Viral suppression following switch to second-line antiretroviral therapy: the role of resistance and ‘sub-therapeutic’ drug concentrations prior to switch. Journal of Infectious Diseases J Infect Dis. 2013 Aug 13.
Link:
http://www.ncbi.nlm.nih.gov/pubmed/23943851
 
Moore PL, Sheward D, Nonyane M, Ranchobe N, Hermanus T, Gray ES, Abdool Karim SS, Williamson C, Morris L. (2013). Multiple pathways of escape from 1 HIV broadly cross-neutralizing V2-dependent antibodies. Journal of Virology May; 87(9):4882-94
Link:
http://www.ncbi.nlm.nih.gov/pubmed/23408621

Ping L-H, Joseph S, Anderson JA, Abrahams M-R, Salazar-Gonzalez JF, Kincer LP, Treurnicht FK, Arney L, Ojeda S, Zhang M, Keys J, Potter EL, Chu H, Moore PL, Salazar-Gonzalez M, Lyer S, Jabara C, Kirchherrr J, Mapanje C, Ngandu N, Seoighe C, Hoffman I, Gao F, Tang Y, Labranche C, Lee B, Savillle A, Vermeulen M, Fiscus S, Morris L, Abdool Karim SS, Haynes BF, Shaw GM, Korber BT, Hahn BH, Cohen MS, Montefiori D, Williamson C, Swanstrom R and the CHAVI. (2013). Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design. J. Virol. July vol. 87 no. 13 7218-7233

Link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Comparison+of+Viral+Env+Proteins+from+Acute+and+Chronic+Infections+with+Subtype+C+Human+Immunodeficiency+Virus+Type+1+Identifies+Differences+in+Glycosylation+and+CCR5+Utilization+and+Suggests+a+New+Strategy+for+Immunogen+Design